SUNDAY, JUNE 17, 2018

Study of key HIV antibodies could lead to new vaccine design

A study of how the most robust antibodies work to block HIV as it seeks entry into healthy cells has revealed a new direction for researchers hoping to design an effective vaccine, ScienceDaily reported Nov. 10.

"Our study clearly showed that we've been overlooking a very important component of antibody function," said S. Munir Alam, an associate professor of medicine at Duke University Medical Center and lead author of the paper appearing in the Proceedings of the National Academy of Sciences.

Alam, a member of the Duke Human Vaccine Institute and study senior author Bing Chen, assistant professor of pediatrics at Harvard Medical School and Children's Hospital Boston, studied two potentially powerful antibodies against HIV, 2F5 and 4E10.

Both of these are rare, broadly neutralizing antibodies, meaning that they can block several different strains of HIV. They accomplish that by binding to the "Achilles heel" of the virus — the so-called outer coat membrane proximal region — part of the outer protein coating next to the viral membrane that opens up and is exposed to the antibodies for just a few minutes during the process of cell fusion and infection.

But the problem for infection control is that such powerful antibodies are rare in HIV infection, and current experimental vaccines have been unable to generate such antibodies. In addition, the window of opportunity for such antibodies to act is very narrow.

"The target region on the virus is only open for a few minutes — maybe 15 minutes or less," Alam said. "Unless the antibody is very close by and ready to home in on it, it won't work. That means our goal has to be the creation of a vaccine that can induce a whole lot more of these antibodies and have them ready to go at the earliest moment of infection."

"Fortunately, our study gave us new information that will help us accomplish this goal," Chen said.

The research team is already working on designing a vaccine that incorporates a lipid component.

"New vaccine designs trials based on these observations are now ongoing in animals," said Barton Haynes, co-author and director of the Vaccine Institute.

The study was funded by a Collaboration for AIDS Vaccine Discovery grant to Duke and Harvard universities from the Bill and Melinda Gates Foundation and grants from the National Institutes of Health.

Organizations in this Story

National Institutes of Health

Want to get notified whenever we write about National Institutes of Health ?
Next time we write about National Institutes of Health, we'll email you a link to the story. You may edit your settings or unsubscribe at any time.